Study Phase 4

Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone

  • 1 CSR Summary Not Available
  • 1 NCT01855074
  • 1 Primary Citation Not Available
  • Data Specification Not Available

Trial Information

Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaBehaviors and Mental DisordersEnrollment80% Female40.5%% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRISSCH4186Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)43

Supporting Documentation

  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the statistical analysis plan, and full clinical study report are available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.